SecBot SecBot
8-K ·Filed Jun 16, 2026

PVLA

PALVELLA THERAPEUTICS, INC.
NEUTRAL
Impact 2/10
Horizonmonths Processed5mo ago SEC0001104659-26-074338
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

No immediate trading catalyst. Monitor future equity grant activity under the expanded plan for potential dilution. The filing confirms routine corporate governance and no changes to executive team or strategy.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$110.12
T+0 close · Jun 16, 2026 · via day close
Latest settled
+36.57%
T+60 · $150.39
Vs SPY
+35.57%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 16 $110.12entry
  2. T+1 · 5mo ago +2.28%α +3.53% · $112.63
  3. T+5 · 5mo ago +7.77%α +10.01% · $118.68
  4. T+20 · 4mo ago +35.92%α +35.72% · $149.68
  5. T+60 · 2mo ago +36.57%α +35.57% · $150.39
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Palvella Therapeutics held its 2026 Annual Meeting on June 10, 2026, where shareholders approved an amendment to the 2024 Equity Incentive Plan to increase authorized shares by 750,000 (approximately 5.2% of outstanding shares). All director nominees were elected, Ernst & Young was ratified as auditor, and advisory votes on executive compensation and frequency were approved. This is a routine governance filing with no material financial or operational impact.

Key Facts

  • Shareholders approved an amendment to the 2024 Equity Incentive Plan, increasing authorized shares by 750,000.
  • Class III directors George M. Jenkins, Todd C. Davis, and John Doux, M.D. were elected with strong support.
  • Ernst & Young LLP was ratified as independent auditor for fiscal 2026 with 11,557,687 votes for.
  • Advisory vote on named executive officer compensation passed with 10,008,180 votes for.
  • Board determined to hold advisory say-on-pay votes annually based on shareholder preference.
  • Plan amendment became effective immediately upon stockholder approval on June 10, 2026.

Financial Impact

No immediate financial impact. The 750,000 share increase represents potential future dilution of ~5.2% of current outstanding shares (14,323,686) through equity grants.

dilution

Risk Factors

  • Potential dilution from future equity awards under the expanded plan.
  • No material operational or financial updates in this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-074338
Document: tm2618003d1_ex10-1.htm0001104659-26-074338
Document: 0001104659-26-074338-index-headers.html0001104659-26-074338
Document: 0001104659-26-074338-index.html0001104659-26-074338
Document: 0001104659-26-074338.txt0001104659-26-074338

Track record

36 reports on PVLA

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 8 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
  2. Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
  3. Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 Now $144.60 −7.81% settles Dec 4
  4. Nov 5, 202611d ago Press Release Neutral 6/10 No price data
  5. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
  6. Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  7. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  8. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  9. Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
  10. Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens in 5h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 16, 2026